B7H3-Targeted Molecular Imaging for Highly Specific Diagnosis and In Vivo Noninvasive Detection of B7H3 in Breast Cancer.

Authors

Lei Xia, Ying Gong, Chengxue He, Bo Mei, Yan Zhang, Nina Zhou, Xiangxi Meng, Hua Zhu, Nan Li, Guohong Song, Zhi Yang

Published in

Journal of nuclear medicine : official publication, Society of Nuclear Medicine. Oct 15, 2026. Epub Oct 15, 2026.

Abstract

B7 homolog 3 (B7H3) is widely expressed in solid tumors, but its role in the diagnosis of breast cancer is unclear. We aimed to evaluate the diagnostic performance of [⁶⁸Ga]Ga-B7H3-BCH PET/CT in breast cancer patients. Methods: Thirty patients with diverse subtypes of breast cancer underwent both [⁶⁸Ga]Ga-B7H3-BCH and [¹⁸F]FDG PET/CT. Immunohistochemical staining for B7H3 was performed in 25 patients. Results: B7H3 positivity was detected in 84% of samples by immunohistochemistry. [⁶⁸Ga]Ga-B7H3-BCH demonstrated a higher lesion detection rate compared with [¹⁸F]FDG (96.8% vs. 92.4%) among 157 lesions. Median SUV_max was 9.5 in strongly positive lesions; bone metastases had the highest uptake (median SUV_max, 10.9). Imaging resulted in changing the stage or treatment in 8 patients. Hormone receptor-positive/human epidermal growth factor receptor 2-negative lesions showed the highest B7H3 positivity (87.5%) and uptake (median SUV_max, 10.5). Conclusion: [⁶⁸Ga]Ga-B7H3-BCH PET/CT offers high sensitivity for staging advanced breast cancer and noninvasive B7H3 screening. It may influence clinical decisions and appears to reveal subtype-specific uptake, with a tendency to favor hormone receptor-positive/human epidermal growth factor receptor 2-negative disease.

PMID:
42880960
Bibliographic data and abstract were imported from PubMed on 16 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.